Security key
230031106
Cullinan Therapeutics, Inc. - COMMON STOCK (CGEM)
CUSIP: 230031106
Q3 2023 13F Holders as of 30 Sep 2023
- Security type / class
- Equity / COMMON STOCK
- Total 13F shares
- 38,010,712
- Total 13F value
- $344,003,620
- Share change
- +1,317,273
- Put/Call ratio
- 212%
- SEC-reported price per share
- $9.05
- Number of holders
- 104
- Value change
- +$11,040,871
- Number of buys
- 46
- Number of sells
- 43
- Shares outstanding
- 61,708,871
Holder snapshot
7 signals
Open additional details 1 more signal available
Security identity
Names, identifiers, and filing context for this profile.
1 source field
Report period
Q3 2023
Institutions
104
Top holders
10
CGEM full security history
Ownership snapshot
Full 13F holder table
Newer quarter: Q3 2026
Cullinan Therapeutics, Inc. SEC filings
Cullinan Therapeutics, Inc. company facts
Broader feeds
Reporting periods
Holder history for CUSIP 230031106
Recent filing periods:
Ownership snapshot
Top reported holders of CGEM - Cullinan Therapeutics, Inc. - COMMON STOCK (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
UBS Oncology Impact Fund ...
Disclosed value leader
Ansbert Gadicke
Comparable rows
0/15
Latest evidence
30 Jun 2023
3/4/5
13F
Highest disclosed value: $102,717,212
15 rows are not safely comparable across share classes.
Showing 1-6 of 15 holder rows.
Quick read
Ansbert Gadicke has the largest disclosed position value at $102.72M.
0 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens Ansbert Gadicke's linked filing trail.
Disclosed position value
Top 5
UBS Oncology Impact Fund L.P.
$95.3M
Morana Jovan-Embiricos
$56.4M
Vision Scs F2
$55.78M
F2 Bioscience I 2017 Ltd
$55.21M
BVF PARTNERS L P/IL
$799.4K
Value bars compare disclosed positions; verify each figure against the linked filing evidence.
Detailed SEC evidence table Showing 1-6 of 15 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| UBS Oncology Impact Fund L.P. |
3/4/5
10%+ Owner
|
—
denominator unverified
|
$95,297,419
7,648,268 shares
|
— | 16 Sep 2021 |
| Morana Jovan-Embiricos |
3/4/5
10%+ Owner
|
—
denominator unverified
|
$56,397,201
4,526,260 shares
|
— | 24 Jun 2022 |
| Vision Scs F2 |
3/4/5
10%+ Owner
|
—
denominator unverified
|
$55,775,322
4,476,350 shares
|
— | 02 Aug 2022 |
| F2 Bioscience I 2017 Ltd |
3/4/5
10%+ Owner
|
—
denominator unverified
|
$55,209,813
4,430,964 shares
|
— | 21 Jun 2022 |
| BVF PARTNERS L P/IL |
3/4/5
10%+ Owner
|
—
mixed-class rows
|
$799,446
94,161 shares
mixed-class rows
|
— | 19 Jan 2023 |
| Ansbert Gadicke |
3/4/5
Director
|
—
denominator unverified
|
$102,717,212
8,243,757 shares
|
— | 22 Jun 2022 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
13F holder rows
Institutional holders as of Q3 2023
Investor-level positions for this CUSIP, loaded as an interactive table.
Institutions
104
Shares
38,010,712
Rows available
104
| Investor | Option | Weight % | Change % | SEC-reported value | * Price | Shares | Share Change | Activity | Report Period |
|---|
* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.
Compare Q3 2023 vs Q2 2023 Across Filers
Q2 2023 holders
102
Q3 2023 holders
104
Holder diff
2
| Investor | Q2 2023 Shares | Q3 2023 Shares | Share Diff | Share Chg % | Q2 2023 value | Q3 2023 value | Value change | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend